HIMS Stock Overview
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals.
Hims & Hers Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.80|
|52 Week High||US$25.40|
|52 Week Low||US$6.57|
|1 Month Change||-12.82%|
|3 Month Change||-13.71%|
|1 Year Change||-35.36%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-30.61%|
Recent News & Updates
Hims & Hers: Great Business, Greater Opportunity
As the lowest cost provider in a growth sector, Hims has the potential to become a major player in the future of Telemedicine. Hims has increased sales at a CAGR of over 77% since inception. There is still ample opportunity for further revenue growth as the market is large and growing. The company has strong branding, customer loyalty, increasing sales, a large gross margin, and a growing subscriber base. Margins may shrink in the future as the company incurs a mix shift towards lower margin distributer selling and less via direct to consumer. This has not been mentioned to substantially affect margins, but it is a possibility. An important risk to note is Telemedicine is a low barrier to entry industry and as a result, Hims could face increased competition in the future.
Hims & Hers Health Stock: An Opportunity After Large Sell-Off
Telehealth concern Hims & Hers Health, Inc. has experienced an approximate 65% share price decline since February 2021 even though it raised its FY21 revenue outlook twice. Despite its impressive growth, many are skeptical it can expand its business model outside the treatment of stigmatized conditions. With few barriers preventing deep-pocketed competitors from entering its space, a recognized brand, and insider buying, this busted IPO merited a deeper dive. A full investment analysis is provided in the paragraphs below.
Hims & Hers Health: An Amazing Bargain Price For This High Growth Stock
As high-growth names start to make a comeback, investors would do well to consider this healthcare stock. Hims is likely to smash through its 30% revenue growth rate expectations in 2022. At just 5x next year's revenues, for a company that isn't that unprofitable, this stock is worthwhile buying.
Time To Buy Hims & Hers
Hims & Hers is a consumer healthcare brand targeting young digitally native consumers and stigmatized disorders. Hims & Hers management is building a track record of strong growth, scalability, and underpromising and overdelivering. Hims & Hers trades is close to all-time-lows.
|HIMS||US Healthcare||US Market|
Return vs Industry: HIMS underperformed the US Healthcare industry which returned 20.7% over the past year.
Return vs Market: HIMS underperformed the US Market which returned 23.3% over the past year.
|HIMS Average Weekly Movement||8.5%|
|Healthcare Industry Average Movement||6.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.0%|
|10% least volatile stocks in US Market||2.3%|
Stable Share Price: HIMS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: HIMS's weekly volatility (8%) has been stable over the past year.
About the Company
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care.
Hims & Hers Health Fundamentals Summary
|HIMS fundamental statistics|
Is HIMS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HIMS income statement (TTM)|
|Cost of Revenue||US$54.36m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.40|
|Net Profit Margin||-35.74%|
How did HIMS perform over the long term?See historical performance and comparison
Is Hims & Hers Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HIMS ($6.8) is trading below our estimate of fair value ($23.33)
Significantly Below Fair Value: HIMS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HIMS is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: HIMS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HIMS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HIMS is overvalued based on its PB Ratio (3.9x) compared to the US Healthcare industry average (2.8x).
How is Hims & Hers Health forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HIMS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HIMS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HIMS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HIMS's revenue (29% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: HIMS's revenue (29% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HIMS is forecast to be unprofitable in 3 years.
How has Hims & Hers Health performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: HIMS is currently unprofitable.
Growing Profit Margin: HIMS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if HIMS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare HIMS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HIMS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (32.5%).
Return on Equity
High ROE: HIMS has a negative Return on Equity (-23.01%), as it is currently unprofitable.
How is Hims & Hers Health's financial position?
Financial Position Analysis
Short Term Liabilities: HIMS's short term assets ($274.2M) exceed its short term liabilities ($52.5M).
Long Term Liabilities: HIMS's short term assets ($274.2M) exceed its long term liabilities ($12.4M).
Debt to Equity History and Analysis
Debt Level: HIMS is debt free.
Reducing Debt: HIMS had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HIMS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if HIMS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Hims & Hers Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HIMS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HIMS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HIMS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HIMS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HIMS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andrew Dudum (32 yo)
Mr. Andrew Dudum is Chairman of the Board and Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded of Hims, Inc. and...
CEO Compensation Analysis
Compensation vs Market: Andrew's total compensation ($USD26.58M) is above average for companies of similar size in the US market ($USD3.67M).
Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.
Experienced Management: HIMS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: HIMS's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Hims & Hers Health, Inc.'s employee growth, exchange listings and data sources
- Name: Hims & Hers Health, Inc.
- Ticker: HIMS
- Exchange: NYSE
- Founded: 2013
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$1.403b
- Shares outstanding: 203.91m
- Website: https://www.forhims.com
Number of Employees
- Hims & Hers Health, Inc.
- 2269 Chestnut Street
- Suite 523
- San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/30 00:31|
|End of Day Share Price||2021/11/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.